Hayley Virgil | Authors


Adjuvant Nivolumab Plus Ipilimumab Combo For Late-Stage Melanoma Did Not Meet RFS End Point

April 11, 2021

The combination adjuvant treatment of ipilimumab plus nivolumab did not meet the dual primary endpoints of the phase 3 CheckMate-915 trial, failing to improve relapse-free survival in the intent-to-treat and PD-L1 of less than 1% populations.

Adjuvant Osimertinib Does Not Adversely Affect Health-Related QOL for EGFR+ NSCLC

February 15, 2021

Patients with EGFR-positive non–small cell lung cancer who received treatment with osimertinib following surgery versus placebo experienced no clinically meaningful differences in health-related quality of life, according to results of a pivotal phase 3 trial.

Atezolizumab, Chemo Combo Improves Outcomes Without Adding Treatment Burden in Early TNBC

December 11, 2020

Neoadjuvant atezolizumab added to nab-paclitaxel followed by doxorubicin plus cyclophosphamide improved pathologic complete responses compared with placebo plus chemotherapy in patients with early triple-negative breast cancer without adding additional treatment burden.

PreciseDx Accurately Classifies Low-Risk Recurrence Scores in Breast Cancer

December 10, 2020

PreciseDx, an artificial intelligence–digital breast cancer risk discrimination platform, was able to classify patients with Oncotype Dx low-risk recurrence scores with high accuracy using only hematoxylin and eosin stain images and limited clinical data.

GTB-3550 TriKE Safely Drives NK Cell Function in MDS, AML

December 08, 2020

Data from initial dose cohorts of a phase 1/2 trial indicated the agent was found to safely drive natural killer cell proliferation in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia.